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Abstract
Background: Clinical vignettes are often used to elicit information about health conditions in research studies. This
review summarizes the components of clinical vignettes describing Alzheimer’s disease (AD) or other dementias.
The purpose is to provide recommendations for the development of standardized vignettes that may be used in
future studies.
Methods: MEDLINE, EMBASE, PsycINFO, ASSIA, CINAHL were searched from their inception to June 2014. Primary
English-language studies employing vignettes to describe AD or similar disorders (including other dementias and
Parkinson’s disease) were included in the review. Included studies had to describe the content of the vignettes in
the published manuscripts. The characteristics of the included studies and the vignettes were extracted in tabular
form and summarized qualitatively.
Results: Forty-two studies were included in the review. Twenty-four of the studies contained at least one AD vignette,
11 had vignettes focusing on non-AD dementias, and seven contained vignettes describing conditions other than
dementia. In total, 58 vignettes were obtained from the 42 included studies.
Conclusions: Key aspects to consider when constructing vignettes for AD or other dementias include writing the
vignettes from a third-person perspective and presenting hypothetical patients as being at least 65 years of age.
Researchers should develop standardized vignettes for use across studies.
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Background
Dementia is a condition affecting higher cortical and
cognitive functions, including memory, learning capabil-
ity, judgment, emotional control, and social behaviour.
Alzheimer’s disease (AD) is the most common form of
dementia in elderly adults, accounting for about sixty
percent of cases of dementia [1, 2]. AD is an irreversible
and progressive form of brain disease that eventually
leads to an inability to carry out simple activities of daily
living [3]. A gradual onset of memory impairment,
followed by deterioration in other cognitive areas (e.g.,
language, abstraction, construction), is characteristic
of AD.
In research studies, the signs and symptoms of dis-
eases such as AD can be written as brief descriptions
that illustrate how the diseases manifest themselves in
patients. The descriptions, known as clinical vignettes,
may be used as tools to measure a diversity of variables,
including quality-of-life (QoL), public perceptions of
disease, and variations in healthcare practice across juris-
dictions [4, 5]. For example, Osborne et al. used a vignette
that described an ‘average’ person with schizophrenia to
generate health utility index scores for a QoL study [6]. In
another project, Hudelson employed clinical vignettes to
analyze medical students’ and physicians’ capacities to
identify sociocultural factors that affect health and health
care in persons with conditions such as hypertension or
tuberculosis [7]. Alexander and Becker formally define
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vignettes as “short descriptions of a person or a social situ-
ation which contain precise references to what are thought
to be the most important factors in the decision-making or
judgment-making process of respondents (p. 94)” [8].
In AD, vignettes are especially important for obtaining
proxy information in place of persons with the disease,
whose levels of cognitive deterioration may prevent
them from providing valid responses to certain types of
data collection instruments. For example, persons who
are beyond the mildest state of AD may be cognitively in-
capable of assessing their QoL using an instrument such as
the EQ-5D [9]; the task of estimating QoL becomes more
difficult as cognitive function worsens [10]. Also, caregivers’
proxy estimates of their care recipients’ QoL tend to be
lower than care recipients’ own estimates [11, 12]. Mem-
bers of the general population could become an alternative
source of proxy QoL estimates for persons with AD [13].
To elicit these proxy estimates, members of the general
population could read a vignette describing AD and they
could answer the questions on the EQ-5D as if they had
AD based on the vignette they just read.
An important consideration to make when designing a
vignette-based study is the content of the vignettes.
Vignettes should present realistic situations to maximize
study validity [14, 15]. However, considerations such as
length, wording, and target audiences mean that the
scenarios described in the vignettes are often only partial
representations of the challenges and symptoms that
accompany medical conditions [4]. Studies in the same
disease or treatment domain might lack comparability
if they are based on different vignettes.
Well-designed vignettes can generate results that permit
researchers to make valid inferences about the variables
under study [16] In AD or dementia, filming actors or
real-life cases (e.g., persons with AD or dementia) is an
alternative means of addressing some of the research
questions that one might otherwise use vignettes to
study. However, such films would still likely be partial
representations of the totality of the medical condition,
and the ethical and resource implications of creating
the films might eclipse any incremental benefits related
to the validity of the collected data.
We conducted a scoping review to identify studies that
employed vignettes to describe AD or other dementias.
We summarized vignette characteristics, purposes, and
foci. No previous reviews have been undertaken on this
topic. Our review provides recommendations on how to
construct clinical vignettes for AD or other dementias in
future research projects.
Methods
Data sources and search strategy
We used MEDLINE, EMBASE, PsycINFO, Applied Social
Sciences and Abstracts (ASSIA), and Cumulative Index to
Nursing and Allied Health Literature (CINAHL) to search
the literature from each database’s inception to June 2014.
The search strategy combined “vignette”, “Alzheimer’s
disease”, “Dementia”, and a list of similar disorders. We
incorporated similar disorders into the review to obtain
a broader sample of vignettes from which to draw recom-
mendations about the construction of vignettes for AD or
other dementias. We felt the design and content of as
many vignettes as possible should be studied to optimize
our recommendations. The complete search strategy,
developed with the assistance of a medical librarian, is
shown in Additional file 1 along with a comprehensive
list of similar disorders.
Five sources were searched to develop a comprehensive
list of the common outcomes, symptoms, and behaviours
of persons with AD or other dementias [1–3, 17, 18]. After
creating the list, the five sources and the MedlinePlus
Medical Encyclopedia were searched for an extensive
list of similar disorders that had at least three out-
comes, symptoms, or behaviours that resembled AD
or other dementias [19]. At least one of the similar
characteristics had to be a decline in cognitive func-
tion relating to memory, language, recognition, motor
function, or executive function (i.e., planning, organiz-
ing, abstracting). Our approach led to three groups of
vignettes in the review: vignettes for AD, vignettes for
other dementias, and vignettes for disorders that are
similar to AD.
Study selection criteria
The articles identified through the database searches
were included in the review if they satisfied all of the
following criteria:
(1)Reported data from a primary study;
(2)Used vignettes describing AD, another form of
dementia, or a similar disorder in their study
methods;
(3)Contained the text of the vignettes used in the
research, or provided descriptions of the content of
the vignettes; and
(4)Published in English.
We excluded case reports, commentaries, editorials,
letters, and reviews from our study.
Recent work from the Canadian Agency for Drugs
and Technologies in Health does not show that limiting
literature searches to English-language articles will bias
the results of systematic reviews [20].
Study screening and data extraction
Two reviewers (HR and AJ) independently screened each
citation found in the literature search. After removal of
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duplicate citations, the reviewers applied the inclusion and
exclusion criteria by reading the title and abstract of each
article. Articles that met the inclusion criteria, or which
could not be fully assessed based on the information avail-
able in the title and abstract, were promoted to full-text
screening. At full-text screening, the reviewers read the
entire article to assess the inclusion and exclusion criteria.
Disagreements between reviewers were resolved by con-
sensus. We extracted the following information from the
included studies: vignette development, study objectives,
vignette administration methods, point of view used to
describe patients in vignettes (i.e., first-, second-, third-
person), outcomes/symptoms described in the vignettes,
and the characteristics of the hypothetical patients fea-
tured in the vignettes.
Results
Selection of studies
Five hundred and twenty-six citations were identified
through the literature search. After removing 189 dupli-
cates, we screened the titles and abstracts of 337 citations
and removed 214 citations. Of the 123 citations promoted
to full text screening, 42 met the inclusion criteria and
were retained in the review (Fig. 1) [13, 21–61]. Five of the
removed citations [62–66] contained vignettes that were
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Fig. 1 PRISMA flowchart for the selection of articles
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virtually identical to the vignettes that were reported in
two included studies [57, 59].
Forty studies featured at least one published vignette;
two additional studies [24, 40] described the content of
vignettes without reproducing the actual text of these
vignettes. Twelve studies contained more than one vi-
gnette [13, 25, 26, 28, 33, 36, 37, 45–47, 50, 57]; in total,
58 vignettes were identified among the 42 studies.
Study characteristics
Studies were summarized into three tables (Additional file
2: Table S1, S2, and S3) based on the disease described in
the vignettes. Additional file 2: Table S1 contains all 24
studies that included at least one vignette on AD [13,
21–23, 25, 29–31, 33, 36, 39, 41–43, 46–52, 56–59],
Additional file 2: Table S2 contains 11 studies whose vi-
gnettes only focused on other dementias [24, 26, 28, 37,
40, 45, 49, 53, 54, 60, 61], and Additional file 2: Table S3
contains 7 studies whose vignettes focused on conditions
other than AD or dementia [27, 32, 34, 35, 38, 44, 55].
Development of vignettes
Of the studies included in the review, only 12 (29 %)
described the development of the vignettes [21, 22, 34,
35, 37, 42, 50, 55–59]. In general, the authors of these
12 studies tested face validity, content validity, and
feasibility by asking experts in the field (e.g., clinicians
with geriatric and/or psychiatric expertise) to review the vi-
gnettes. The authors of four of the 12 studies pilot-tested
the vignettes on researchers [21], healthcare providers (e.g.,
nurses) with geriatric and psychiatric expertise [34, 35], or
experts in dementia (professional background not identified
in the published article) [42]. No authors reported testing
vignettes on persons with AD or their caregivers.
Study objectives
The primary objectives of the included studies varied
widely. However, most aimed to evaluate patients’ atti-
tudes and beliefs regarding the health conditions that
were described in the vignettes. For example, Kalaitzaki
et al. used vignettes to assess emotional reactions to
AD in health professionals, laypersons, and graduate
students [42]. Additionally, two studies used vignettes
to obtain proxy QoL estimates from community-dwelling
adults in place of persons with AD [13, 55].
The principal use of the vignettes in the included stud-
ies most closely maps onto what Aguinis and Bradley call
the ‘paper people studies’ type of experimental vignette
methodology [67]. For this methodology, researchers pro-
vide participants with vignettes in written form and ask the
participants to make a decision, judgment, or choice that
flows from the content of the vignettes.
Administration of vignettes
The majority of the studies administered the vignettes to
a sample of participants from the general public or to
healthcare professionals (frequently physicians and nurses).
The means of administering the vignettes to partici-
pants were described in 29 [13, 21, 22, 24, 28–33, 38,
43–50, 52–61] of the 42 studies: 12 (41.4 %) [13, 21, 22,
28, 30, 31, 33, 43, 47, 56, 57, 59] presented vignettes to
participants in face-to-face interviews, five (17.2 %) [44,
46, 50, 58, 60] presented vignettes over the telephone,
nine (31 %) [24, 29, 32, 38, 49, 52, 53, 55, 61] presented
vignettes through the mail, and three (10.3 %) [45, 48,
54] presented vignettes through small group discussions.
The remaining thirteen studies did not specifically ex-
plain how the vignettes were administered to partici-
pants; however, some of these studies did mention a
setting within which the administration of the vignettes
took place (e.g., during staff meetings [27] or physician
grand rounds [51]).
The vignettes were used to evaluate a diversity of out-
comes, including social distance (i.e., the perceived degree
of separation between various societal groups such as eth-
nic groups or social classes) [23], treatment options [29],
emotional reactions [42], and QoL [13]. These outcomes
were measured using validated instruments (e.g., EQ-5D-
5 L [9, 13], Quality-of-life – Alzheimer’s Disease scale [13,
68], Perceptions of Restraint Use Questionnaire [43, 69])
or ad hoc questionnaires developed by the authors (e.g., a
five-point scale measuring factors determining physicians’
decision making processes [51], a five-point Likert-type
scale measuring information-seeking, information-giving,
and involvement in patient-physician interactions [60]).
Vignette point of view
Six (10.3 %) of the 58 vignettes were presented to study
participants in the second-person using phrases such as
“If you have Alzheimer’s disease.” Fifty-two (89.7 %) were
presented to participants in the third-person using names
or pronouns (e.g., “Mr. X”, s/he) to label the hypothetical
patients described in the vignettes [13, 32, 33].
Frequency of symptoms described in the vignettes
The 20 most frequently recurring symptoms presented
in the vignettes are reported in Table 1. The five most
common symptoms in the AD vignettes include deterior-
ation of memory, changes in mood, difficulty with activities
of daily living, signs of aphasia (i.e., an inability to under-
stand or express speech), and signs of agnosia (i.e., a loss of
ability to recognize persons, objects, sounds, and smells).
The six most commonly recurring symptoms for non-AD
dementias are deterioration of memory, changes in mood,
disorientation, signs of aphasia, difficulties with activities of
daily living, and withdrawal from social activities (the latter
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three symptoms shared the same frequency, so we reported
six rather than five symptoms). The five most common
symptoms for the non-AD/non-dementia disorders are de-
terioration of long-term memory, deterioration of short-
term memory, signs of aphasia, difficulty with activities of
daily living, and disorientation.
Characteristics of vignette patients
Vignette patient age
Fourteen vignettes did not present the ages of their
hypothetical patients [21, 26, 29, 37, 44, 45, 48, 50, 54, 56].
Age was not applicable for six other vignettes because they
were written in the second-person point-of-view [13, 32,
33]. In one study, the authors varied the age of patients
substantially (i.e., 68 or 28 years of age) to determine
whether older versus younger patients were more likely to
be diagnosed with a cognitive disorder [27]. The mean
(standard deviation [SD]) for patient age among the 33 vi-
gnettes describing AD or another dementia, and reporting
age, was 74 (9) years; and the mean (SD) for patient age
among the four vignettes focused on similar disorders,
and reporting patient age, was 69 (14) years. We excluded
the study by Ciliberto et al. from our computation of mean
age [27].
Vignette patient sex
The sex of the hypothetical patients in the vignettes was
not given for two [29, 44] vignettes and was not applicable
for the six vignettes (published in three articles) written in
the second-person [13, 32, 33]. Of the 50 remaining vi-
gnettes, nine (18 %) (published in seven articles) randomly
assigned the sex of the hypothetical patient [22, 23, 28, 46,
47, 55, 56], 23 (46 %) described the sex as female, and 18
(36 %) described the sex as male. Stratified by vignette
group, of the 41 hypothetical patients assigned a sex: 10
patients were female and 14 patients were male for AD; 10
patients were female and three patients were male for
non-AD dementias; and three patients were female while
one patient was male in vignettes for other conditions.
Table 1 Frequencies of common symptoms and behaviours described in vignettes
AD Vignettes





(n = 4) (n = 4) (n = 4) (n = 33) (n = 16) (n = 9) (n = 58)
Memory Deterioration/Forgetfulness 4 3 1 20 12 7 39
Short-term Memory Deterioration 2 1 1 7 4 5 16
Signs of Aphasia 1 2 1 8 5 4 17
Signs of Agnosia 0 1 1 8 1 2 11
Signs of Apraxia 0 0 0 2 2 1 5
Delusional Behaviour 0 1 1 4 1 0 5
Wandering Behaviour 0 0 1 3 2 1 6
Difficulty with Activities of Daily Living 1 3 1 10 5 4 19
Mood Changes (agitation, aggression, irritability,
depressiveness, anxiety)
1 2 4 15 9 2 26
Declining ability to Concentrate 2 0 0 3 1 1 5
Disorientation (either time, place, or situation) 0 1 1 5 6 4 15
Denial of Condition 0 0 0 2 1 1 4
Incontinence 0 0 0 4 1 0 5
Declining Directional Ability 1 0 0 4 2 3 9
Repetition of Self 0 2 0 4 4 0 8
Withdrawal from Social Activities 2 1 0 3 5 0 8
Confusion 1 0 0 4 4 2 10
Inappropriate/Ill-mannered Behaviour 0 0 0 2 0 0 2
Difficulty Maintaining Self/Self-Appearance 0 2 1 3 3 1 7
Paranoia or Suspicion 0 0 1 2 3 2 7
Notes: Numbers represent the frequency of symptom/behaviour in vignette category, AD Alzheimer’s disease, aphasia represents as inability to understand or
express speech, agnosia presents as a loss of ability to recognize persons, objects, sounds, and smells, and apraxia presents as a lack of ability to execute
purposeful movements
a33 vignettes focused on AD, but only 12 explicitly stated the stage of AD described
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Discussion
Development and content of vignettes
Only a small proportion of the included studies (n = 12)
reported on the development of the vignettes. Without
this information, readers cannot assess whether the au-
thors adequately validated the content of the vignettes.
Since clinical vignettes are intended to accurately depict
health conditions and evoke responses from study partici-
pants, the content validity of the vignettes is of paramount
importance. Inaccurate vignettes will not effectively portray
the characteristics of a disease and will lead to potentially
biased data collection. For example, QoL estimates based
on a vignette that portrays only the worst possible symp-
toms of disease will be biased downward. Future studies
should describe the process of developing new vignettes. In
the case of vignettes borrowed from other studies, the au-
thors should report on how these vignettes were developed
in the other studies.
In addition to explicit methods, another important
consideration when developing vignettes is the degree to
which the new vignettes should be similar to existing vi-
gnettes. A study might require the development of new
vignettes because of the population under investigation
(e.g., members of the general public should read vignettes
written in lay language, whereas vignettes intended for
nurses or clinicians might contain professional jargon).
New vignettes may also be necessary to describe a novel
treatment (e.g., a disease-modifying medication for AD).
However, researchers should attempt to standardize the
mix of symptoms and disease characteristics described
within vignettes that pertain to the same health conditions
[4]. Such standardization will enhance comparability be-
tween studies and encourage reproducibility of results.
Patient age and sex
The mean age for patients, as described in the vignettes,
was 74 years for the vignettes about AD and other demen-
tias and 69 years for the vignettes about other disorders.
These ages reflect the fact that both AD and dementia are
rare in persons under the age of 60 [1, 70]. Estimates have
found that the highest prevalence of AD is above the age
of 75 years [71, 72], with prevalence increasing with age
[73]. Patient age is an important component of clinical
vignettes for AD because it is one of the strongest risk
factors for the disease. Additionally, patient age helps
to situate the context of the disease. For example, older
patients may become more dependent on others to
help with particular activities of daily living (ADL) over
time. Vignettes should therefore describe hypothetical
patients who are at least 65 years of age.
Patient sex is less important to capture in clinical vi-
gnettes for AD. Sex does not affect the presentation
and progression of the disease. Researchers may wish
to match the sex of the hypothetical patient described
in a vignette with the person who is reading the vignette.
This approach might promote the realism of the vignette
and allow study participants to more closely identify with
the content of the vignette.
Patient point-of-view
The majority of vignettes contained in the included studies
were targeted to participants who did not have the disease
of interest. The vignettes were rarely given to participants
who had the disease (seen in only three articles [21, 28,
33]). Most vignettes were written in the third-person, with
hypothetical patients being called by proper names (e.g.,
Donna, David) or generic terms (e.g., “Mr./Mrs. X”, “he”/
“she”, “the patient”). Study participants may regard vi-
gnettes written in the third-person as being more objective
than first- (e.g., “I”) or second-person (e.g., “you”) vignettes.
First- or second-person vignettes might evoke doubt or
disbelief on the part of study participants, who would
be imagining themselves as patients in what are known
to be fictitious situations [4, 15]. Vignettes should be
written in the third-person point-of-view to portray realistic
scenarios for the reader.
Vignette content
The characteristics of hypothetical patients varied sub-
stantially across vignettes. Even the 20 most frequently
recurring characteristics across all 58 vignettes did not
appear in every vignette (for example, Karlsson and col-
leagues used a vignette with none of the 20 characteristics
[43]), while as many as nine of these characteristics ap-
peared in some vignettes (i.e., Holroyd et al.’s vignette
contained nine of the 20 characteristics among all de-
scribed symptoms [41]). Two reasons account for this
variation. First, some characteristics might not be relevant
for the purpose of the research. For example, Hebert and
colleagues investigated caregivers’ experiences with driving
and dementia patients [39]. Understandably, the study’s
vignette focused on symptoms related to this objective
(e.g., disorientation to location), as opposed to symptoms
that may not provide the reader with relevant information
(e.g., paranoia). Many vignettes were drafted to meet nar-
row and specific study objectives. These vignettes were
not developed to describe broad constellations of symp-
toms. Second, no guidelines exist to govern the design of
clinical vignettes for AD. For example, vignettes do not
have a set length. Two [25, 38] of the included studies re-
ported their vignette length, effectively demonstrating the
variability amongst the total vignette population. Cairns
et al. [25] reported vignette length as ranging from 330 to
1018 words (mean 782 words), whereas Harden and col-
leagues [38] reported vignette length as ranging from only
60 to 80 words. Differences in length affect the amount of
content in the vignettes. Longer vignettes can describe
more symptoms, or they can expand on the descriptions
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of a select number of symptoms. However, longer vignettes
will increase the amount of time required of participants to
complete the study’s tasks. Increased time commitments
could create disincentives to participate in research, or lead
to greater amounts of missing data because participants
do not complete lengthy surveys. Researchers must bal-
ance the amount of vignette content with the practical
requirements of recruiting participants and obtaining
complete data.
Notwithstanding vignettes developed for very narrow
and specific purposes, the goal of researchers in AD or
other dementias should be to promote the standardization
of the content of vignettes. Standardization enhances
inter-study comparability and lends itself to the produc-
tion of evidence syntheses such as systematic reviews and
meta analyses, which are important tools to inform clinical
and policy decisions in health care [74, 75]. Many research
topics in AD or other dementias lend themselves to the
use of standardized vignettes. Examples include the use of
proxy respondents to obtain measures of the QoL of per-
sons with AD or to elicit attitudes to AD (e.g., should the
healthcare system devote more resources to AD versus
coronary heart disease?). Proxy respondents might include
members of the general population, caregivers in AD, or
health professionals. Careful selection of hypothetical pa-
tient characteristics is required because the content of the
vignettes will shape proxy respondents’ responses to study
questionnaires.
Standardized vignettes could be developed for individual
research areas. For QoL, as an example, researchers could
create sets of vignettes describing hypothetical patients
with the characteristics that map onto the domains
contained in QoL instruments such as the EQ-5D [9],
SF-36 [76], and QoL-AD [68]. Any QoL research involving
a certain instrument would utilize the set of vignettes devel-
oped to match the content of the instrument in question.
Such purposeful selection of content helps to overcome the
variability in vignettes that is motivated by the heteroge-
neous clinical manifestations of AD or other dementias.
Researchers should employ focus groups or one-on-one
interviews to assess the content validity of newly developed
vignettes. Participants for these validity studies should be
drawn from the same sample frame as the persons who
would be approached to participate in a ‘full’ study. These
participants would read the vignettes under consideration
and respond to semi-structured interview questions about
content (e.g., should items be added or deleted from the vi-
gnettes), length, wording, and formatting (e.g., paragraph
form versus point form). Focus groups provide a forum for
participants to validate one another’s ideas and build upon
each other’s thoughts. One-on-one interviews are an ideal
forum for in-depth probes about the vignettes without the
distractions of the group approach (e.g., dominance by one
or two group members, shyness in social situations as an
obstacle to giving feedback in group settings). Researchers
may wish to consider a mix of focus groups and one-on-
one interviews, and they should report their methods of
validating their vignettes.
Researchers should assess newly developed vignettes
for response consistency and vignette equivalence before
using the vignettes in their studies. Response consistency
is the extent to which participants provide equivalent
ratings of some aspect of their personhood (e.g., their
health) when asked (1) to directly rate the aspect and (2)
to rate the same aspect, but this time after reading a vi-
gnette description of the aspect [77]. Vignette equivalence
is the extent to which all participants rate a vignette’s de-
scription in the same way [78]. Equivalence is often
assessed by verifying whether participants’ ratings of the
same description remain stable after changing an inconse-
quential component of the vignette text (e.g., changing
from a male to a female name in a third-person vignette
describing mild AD).
Conclusions
Key aspects to consider when constructing a vignette for
AD or another dementia include:
(1)Vignettes should be written from the third-person
perspective, although the sex of the hypothetical
patients described in the vignettes could be altered
to match individual study participants;
(2)The patient should be presented as being equal to or
greater than 65 years of age; the mean patient age
described in the literature is 72 years of age; and
(3)Where possible, vignettes should contain
standardized descriptions of hypothetical patients.
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